Literature DB >> 10894940

Fine mapping of the human preprocortistatin gene (CORT) to neuroblastoma consensus deletion region 1p36.3-->p36.2, but absence of mutations in primary tumors.

K Ejeskär1, F Abel, R Sjöberg, J Bäckström, P Kogner, T Martinsson.   

Abstract

The processed product of the human gene preprocortistatin, the peptide cortistatin-17 (hCST-17), bears a strong structural resemblance to the peptide somatostatin (SST), which has an identical receptor binding domain. CST has affinity to all known SST receptor (SSTR) subtypes. Expression of both SST and its receptors has been shown in previous studies to have biological and clinical significance in neuroblastomas, with a putative role in tumor differentiation and apoptosis in vivo. In this work we have employed radiation hybrid mapping and BAC physical mapping to map the human preprocortistatin gene (CORT) to chromosome region 1p36.3-->p36.2, close to the genetic marker D1S244. D1S244 defines the centromeric border of the smallest region of overlap of deletion in our primary neuroblastoma material. We have also defined the genomic sequence of the gene by BAC sequencing and found that preprocortistatin consists of two exons divided by a 1-kb intron. Two polymorphic sites, neither of which causes amino acid exchange, have been detected in the coding region of the gene. Expression studies showed that preprocortistatin is expressed in neuroblastomas of all different stages, as well as in ganglioneuromas. Through genomic sequencing we made mutation analyses of exonic sequences in 49 primary neuroblastomas of all different stages, but no mutations could be detected. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10894940     DOI: 10.1159/000015566

Source DB:  PubMed          Journal:  Cytogenet Cell Genet        ISSN: 0301-0171


  8 in total

Review 1.  New roles of a neuropeptide cortistatin in the immune system and cancer.

Authors:  Min Li; Shaoyu Yan; William E Fisher; Changyi Chen; Qizhi Yao
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

2.  Presence of cortistatin in the human pancreas.

Authors:  M Papotti; E Tarabra; E Allia; F Bozzalla-Cassione; F Broglio; R Deghenghi; E Ghigo; G Muccioli
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

3.  Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death.

Authors:  Katarina Ejeskär; Cecilia Krona; Helena Carén; Faten Zaibak; Lingli Li; Tommy Martinsson; Panayiotis A Ioannou
Journal:  BMC Cancer       Date:  2005-12-16       Impact factor: 4.430

4.  Analyses of apoptotic regulators CASP9 and DFFA at 1P36.2, reveal rare allele variants in human neuroblastoma tumours.

Authors:  F Abel; R-M Sjöberg; K Ejeskär; C Krona; T Martinsson
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

5.  Effects of octreotide and insulin on colon cancer cellular proliferation and correlation with hTERT activity.

Authors:  Georgios D Ayiomamitis; George Notas; Apostolos Zaravinos; Ioannis Drygiannakis; Maria Georgiadou; Ourania Sfakianaki; Niki Mastrodimou; Kyriaki Thermos; Elias Kouroumalis
Journal:  Oncoscience       Date:  2014-06-30

6.  A novel 1p36.2 located gene, APITD1, with tumour-suppressive properties and a putative p53-binding domain, shows low expression in neuroblastoma tumours.

Authors:  C Krona; K Ejeskär; H Carén; F Abel; R-M Sjöberg; T Martinsson
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

7.  A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation.

Authors:  Helena Carén; Katarina Ejeskär; Susanne Fransson; Luke Hesson; Farida Latif; Rose-Marie Sjöberg; Cecilia Krona; Tommy Martinsson
Journal:  Mol Cancer       Date:  2005-03-01       Impact factor: 27.401

8.  Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours.

Authors:  H Carén; S Fransson; K Ejeskär; P Kogner; T Martinsson
Journal:  Br J Cancer       Date:  2007-10-16       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.